Jaffuel Dany, Nogue Erika, Roubille François, Mallet Jean-Pierre, Bailly Sébastien, Goupil François, Thomas Audrey, Hervé Carole, Masson Philippe, Bizieux-Thaminy Acya, Blanchard Margaux, Kerbrat Sandrine, Sabil Abdelkebir, Trzepizur Wojciech, Roubille Camille, Skinner Sarah, Bourdin Arnaud, Molinari Nicolas, Gagnadoux Frédéric
Department of Pneumology, Arnaud de Villeneuve, Regional University Hospital of Montpellier, Montpellier, France.
PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France.
ERJ Open Res. 2025 Aug 4;11(4). doi: 10.1183/23120541.00081-2025. eCollection 2025 Jul.
The impact of positive airway pressure (PAP) therapy on the use of oral antihypertensive drugs (OAHDs) in patients with obstructive sleep apnoea (OSA) remains unclear. This study aimed to evaluate the association between PAP use and the delivery of OAHDs.
Data from the Pays de la Loire Sleep Cohort were linked with the French health insurance database to quantify OAHD delivery in patients with hypertension at the initiation of PAP therapy. The primary end-point was the change in OAHD score, reflecting the number of OAHD classes delivered. PAP use groups were defined as: termination, 0-<4 h·day, 4-<6 h·day and ≥6 h·day.
The study included 2205 OSA patients (median (Q1-Q3) apnoea-hypopnea index of 39 (30-55) events·h), of whom 68% were male. The median age was 61 (54-68) years, the body mass index (BMI) was 32.42 (28.95-36.43) kg·m and the Epworth score was 10 (6-13). After 1 year of PAP, the mean±sd OAHD score decreased from 2.16±1.11 to 2.13±1.18 with no significant difference between PAP use groups. Respectively, 11.93% and 11.07% of patients experienced a decrease or increase in OAHD score, with no significant difference between PAP use groups. Multivariate analysis revealed that an increase in OAHD score was significantly positively associated with age, usage of calcium channel blockers and number of consultations. A decrease in OAHD score was significantly associated with baseline OAHD score, number of consultations, use of loop diuretics and a decrease in medication possession ratio.
PAP use is not associated with a change in OAHD score after 1 year.
气道正压通气（PAP）治疗对阻塞性睡眠呼吸暂停（OSA）患者口服抗高血压药物（OAHDs）使用的影响尚不清楚。本研究旨在评估PAP使用与OAHDs给药之间的关联。
卢瓦尔河地区睡眠队列的数据与法国健康保险数据库相关联，以量化PAP治疗开始时高血压患者的OAHD给药情况。主要终点是OAHD评分的变化，反映所提供的OAHD类别数量。PAP使用组定义为：终止使用、每天0至<4小时、每天4至<6小时和≥6小时。
该研究纳入了2205例OSA患者（呼吸暂停低通气指数中位数（Q1-Q3）为39（30-55）次/小时），其中68%为男性。中位年龄为61（54-68）岁，体重指数（BMI）为32.42（28.95-36.43）kg/m²，Epworth评分是10（6-13）。PAP治疗1年后，平均±标准差OAHD评分从2.16±1.11降至2.13±1.18，各PAP使用组之间无显著差异。分别有11.93%和11.07%的患者OAHD评分下降或上升，各PAP使用组之间无显著差异。多变量分析显示，OAHD评分增加与年龄、钙通道阻滞剂的使用及会诊次数显著正相关。OAHD评分降低与基线OAHD评分、会诊次数、襻利尿剂的使用及药物持有率降低显著相关。
PAP使用1年后与OAHD评分变化无关。
